Yes gettting reimbursement/funding for new tests in the institutional settings and other agencies has many hurdles. Getting regulatory approval is only the first step. A product will not "take off" until the specialised commitees which usually are stacked with conservative clinicians as well as the "bean counters" finally are convinced of the cost / benefits. Only rarely do products appear that get priority funding. It all takes time and a lot of evidence.
- Forums
- ASX - By Stock
- CST
- it aint so easy
it aint so easy, page-7
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CST (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.90M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4500 | 7.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 31094 | 1 |
Last trade - 11.00am 02/12/2024 (20 minute delay) ? |
Featured News
CST (ASX) Chart |
Day chart unavailable
The Watchlist
NXD
NEXTED GROUP LIMITED
Nick Poll, Managing Director
Nick Poll
Managing Director
SPONSORED BY The Market Online